https://www.selleckchem.com/products/lf3.html
BACKGROUND Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients. METHODS Adults aged ≥65 years previously vaccinated with ZVL ≥5 years before (HZ-PreVac, N=215) were group-matched with ZVL-naïve individuals (HZ-NonVac, N=215) and vaccinated with RZV. Glycoprotein E (gE)-specific humoral and cell-mediated immune (CMI) responses and the correlation between them, polyfunctional gE-speci
Like
Comment
Share
